Aktis Oncology, Inc. (AKTS) stock
AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$16.31+0.15 (+0.93%)
Close on Nov 17, 2026Market cap $907.15MP/E –Yield –
Aktis Oncology profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -766.7% | +362.3 |
| Q2 FY2026 | Jun 30, 2026 | -713.5% | +322.1 |
| Q1 FY2026 | Mar 31, 2026 | -567.9% | – |
| Q3 FY2025 | Sep 30, 2025 | -983.7% | – |
| Q2 FY2025 | Jun 30, 2025 | -1129.0% | – |
| Q1 FY2025 | Mar 31, 2025 | -1035.6% | – |
See a number that looks wrong?